Tag
NYSE: AZN
- Summit Therapeutics reports 25% lower death risk in biliary-cancer trial
- AbbVie receives two FDA breakthrough designations for Temab‑A
- Eli Lilly and Company wins first-line Jaypirca approval for CLL/SLL
- Summit Therapeutics plans Phase III Datroway breast cancer trial
- Immunome gains FDA IND clearance for IM‑1340 solid tumour study
- AstraZeneca PLC submits US NDA for Orpathys plus Tagrisso
- Summit Therapeutics agrees to US$2B AstraZeneca equity investment
- Arm CEO sees AI accelerating cancer diagnosis, research and treatment